Conference call to provide an overview of TROPOS, its global Phase 2 Clinical Trial to evaluate KER-012 in combination with background therapy in patients with Pulmonary Arterial Hypertension will be held on August 8 at 8 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KROS:
- Keros Therapeutics to host conference call
- Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
- Keros Therapeutics reports Q2 EPS ($1.27), consensus ($1.34)
- Adobe upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- Wedbush bullish on Keros Therapeutics, initiates with an Outperform